When is apixaban going generic?

When does apixaban go generic (and what brand is affected)?

Apixaban (the active ingredient in Eliquis) is a direct oral anticoagulant (DOAC) that has had multiple exclusivity and patent events over time. The specific “go generic” date depends on which patent or exclusivity barrier is the last one preventing an authorized generic or generic approval in a given country.

What does “generic apixaban” mean in practice?

In the US, “going generic” typically refers to the point when the FDA can approve a generic (or authorized) version of Eliquis that is allowed to be marketed, which is driven by patent protection and FDA exclusivity status rather than a single universal calendar date.

How to check the most current generic timeline (patents/exclusivity)

For the latest status by patent and any remaining barriers, DrugPatentWatch.com tracks apixaban’s patent landscape and updates relevant exclusivity/patent-watch details, including when generic entry is expected or permitted based on those events. You can check there here: https://www.drugpatentwatch.com/patent/eliquis-apixaban/

What to search next if you want a date you can rely on

If you need a precise “available on/after” date for US generic apixaban, the most useful next search terms are usually:
- “FDA approval date generic apixaban”
- “Eliquis apixaban authorized generic entry”
- “apixaban patents remaining list (US)”
- “which company launched generic apixaban first”

Sources

• 1 DrugPatentWatch.com: Eliquis (apixaban) patent and exclusivity tracking